Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Inmune Bio is a clinical-stage biotechnology company focused on reprogramming the innate immune system. Its lead program, CORDStrom, targets Recessive Dystrophic Epidermolysis Bullosa (RDEB). Other platforms include XPro1595 for neuroinflammation (Alzheimer's) and INKmune for oncology. The company is a smaller reporting company with no commercial revenue to date.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $50 |
| Net Loss | $(6,680) | $(34,197) |
| Net Loss Per Share (Basic & Diluted) | $(0.25) | $(1.49) |
| Operating Cash Flow | $(6,578) | $(14,199) |
| Cash and Cash Equivalents (End of Period) | $18,411 | $33,374 |
| Total Assets | $26,845 | $32,351 |
| Total Liabilities | $6,483 | $8,827 |
| Stockholders' Equity | $20,362 | $23,524 |
Debt & Liquidity: The company has no long-term debt. Total liabilities consist primarily of accounts payable ($5.05 million) and operating lease liabilities ($1.41 million). As of June 30, 2026, the company held $18.4 million in cash and cash equivalents.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately $27.5 million (79%) compared to the prior year period. This improvement is primarily due to the absence of a $16.5 million impairment charge on acquired in-process research and development (IPR&D) assets recorded in 2025 following the failure of the Alzheimer's Phase 2 trial.
- Research and Development (R&D) Expenses: R&D expenses dropped from $13.4 million in 2025 to $2.8 million in 2026. This decrease is attributed to the completion of the Alzheimer's clinical program in 2025 and a $4.1 million increase in R&D tax rebates recognized in 2026 (primarily from Australia).
- Operating Cash Flow: Cash used in operating activities improved significantly, decreasing from $14.2 million to $6.6 million, driven by lower operating expenses and higher tax rebate receipts.
- Financing Activity: Financing cash inflows dropped from $27.5 million in 2025 to $0.7 million in 2026. In 2025, the company raised significant capital via a registered direct offering ($18.9 million) and ATM sales. In 2026, proceeds were limited to ATM sales ($0.6 million) and warrant exercises ($0.9 million).
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $18.4 million in cash and projected operating losses, the company estimates it will have insufficient liquidity to sustain operations for one year following the issuance of these financial statements.
- Capital Needs: The company is actively evaluating financing strategies, including public or private equity sales, debt financing, government grants, collaborations, or asset divestitures. There is no assurance that additional funding will be available on favorable terms.
- Product Pipeline Status:
- CORDStrom: Transitioning toward regulatory submission. The company intends to file a Marketing Authorization Application (MAA) in the UK by late Q3/early Q4 2026, followed by EU and US filings.
- XPro1595 (Alzheimer's): Development halted due to insufficient resources; the company is seeking a strategic partner to advance the program.
- INKmune: Nearing completion of a Phase II trial for metastatic castrate-resistant prostate cancer.
- Recent Financing Actions: In June 2026, the company executed a warrant inducement agreement, allowing holders to exercise 50% of their warrants at a reduced price ($1.40 vs. $1.95) in exchange for extending the expiration date of the remaining warrants to December 2027. This generated approximately $0.9 million in gross proceeds.
- Risks: Key risks include the inability to secure additional financing, failure to obtain regulatory approval for CORDStrom, and the uncertainty of clinical trial outcomes.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any pending financing agreements or grant applications.
- R&D Tax Rebates: Confirm the timing and certainty of future R&D tax credit receipts from Australia and the UK, which significantly offset operating expenses.
- Regulatory Filings: Monitor the submission dates for the CORDStrom MAA in the UK and subsequent BLA in the US, as these are critical milestones for potential revenue generation.
- Partnership Progress: Track the company's efforts to secure a strategic partner for the XPro1595 Alzheimer's program, as independent advancement is not currently planned.
- Dilution Risk: Assess the potential dilution from future equity raises, given the company's reliance on equity financing and the existence of ~9.7 million outstanding stock options and ~3 million warrants.